Lumos Diagnostics Holdings (ASX:LDX) said its FebriDx rapid point-of-care test is now deployed across 215 live sites in the US, up from 170 previously, as the product's commercial traction continues to advance, according to a Tuesday filing with the Australian bourse.

A further 405 sites are in the evaluation stage, up from 350 previously, per the filing.

Since the company's July update, two additional top 100 US urgent care groups owned by major US health systems have committed to rolling out FebriDx across more than 40 sites, moving these accounts into the network rollout stage, the company said.

It added that two further top 100 urgent care groups are currently advancing clinical and economic validation of the test across more than 45 sites.

Lumos Diagnostics shares soared 15% in recent Tuesday trade.